Treatment of Culture-Negative Skull Base Osteomyelitis
Authors:
- Hamid R DjalilianHDHamid R Djalilian
- Bahman ShamlooBSBahman Shamloo
- Kunal H ThakkarKTKunal H Thakkar
- Mojdeh Najme-RahimMNMojdeh Najme-Rahim
- 1 February 2006
- journal article
- case report
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 27 (2) , 250-255
Abstract
To evaluate the efficacy of a therapeutic regimen in the treatment of patients with culture-negative skull base osteomyelitis. Retrospective case review. Tertiary referral hospital. Eight patients with diabetes mellitus presented with otalgia and were found to have positive technetium and gallium scans of the temporal bone. These patients, however, all had negative cultures of their external auditory canals. All patients had been treated with ototopic drops and two patients had undergone a 2-week course of oral quinolones. All patients were treated with a 6-week course of intravenous ceftazidime or aztreonam for penicillin-allergic patients, oral ciprofloxacin at a higher dose than normal, and topical aminoglycoside steroid drops. Resolution of the temporal bone gallium scan abnormality, recurrence rate, and time to discharge from the hospital. The patients were discharged from the hospital within 4 days from admission. All patients showed resolution of the temporal bone abnormality on the gallium scan at the 6-week time point. The median follow-up period was 6 months, and none of the patients had a recurrence of the infection. The above-described treatment regimen will result in a high cure rate and a short hospitalization period.Keywords
This publication has 14 references indexed in Scilit:
- Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis mediaClinical Otolaryngology, 2004
- Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001Antimicrobial Agents and Chemotherapy, 2003
- Evolving Resistant Pseudomonas to Ciprofloxacin in Malignant Otitis ExternaThe Laryngoscope, 2002
- Comparative pharmacokinetics and safety of ciprofloxacin 400 mg iv thrice daily versus 750 mg po twice dailyJournal of Antimicrobial Chemotherapy, 1994
- Adjuvant Hyperbaric Oxygen in Malignant External OtitisJAMA Otolaryngology–Head & Neck Surgery, 1992
- Ciprofloxacin: Drug of choice in the treatment of malignant external otitis (MEO)The Laryngoscope, 1991
- Efficacy of Oral Ciprofloxacin Plus Rifampin for Treatment of Malignant External OtitisJAMA Otolaryngology–Head & Neck Surgery, 1989
- Atypical osteomyelitis of the skull baseThe Laryngoscope, 1989
- Necrotizing Otitis Externa due to Aspergillus in an Immunocompetent PatientJAMA Otolaryngology–Head & Neck Surgery, 1988
- Pyocyaneous osteomyelitis of the temporal bone, mandible and zygoma.The Laryngoscope, 1959